论文部分内容阅读
目的:观察急性脑梗死患者血浆S-100b蛋白、神经元特异性烯醇化酶(NSE)的浓度变化,评价S-100b与NSE在急性脑梗死中的临床价值。方法:应用ELISA法对34例急性脑梗死患者的血浆S-100b及NSE蛋白水平进行动态检测,同时应用NIHSS进行神经功能缺损评分及CT扫描,并与20例健康体检者进行比较。结果:脑梗死患者血浆NSE浓度在起病第1、3天显著高于对照组(P<0.01),第3天达峰值。脑梗死组患者血浆S-lOOb浓度明显升高,36小时达到峰值。血浆NSE与S-100b含量与梗死灶大小、神经功能缺损程度呈正相关(P<0.01),临床疗效越差血浆NSE含量越高(P<0.01)。结论:急性脑梗死患者血浆NSE与S-100b含量升高,且随病程发展不同时期升高的程度不同,其含量可反映脑梗死的病情程度;NSE与S-100b可以作为脑梗死患者脑损害程度及预后判定的客观指标。
Objective: To observe the changes of plasma S-100b protein and neuron-specific enolase (NSE) in patients with acute cerebral infarction and evaluate the clinical value of S-100b and NSE in acute cerebral infarction. Methods: The levels of plasma S-100b and NSE in 34 patients with acute cerebral infarction were detected by ELISA. Neurological deficit scores and CT scans were performed with NIHSS and compared with 20 healthy subjects. Results: The plasma levels of NSE in patients with cerebral infarction were significantly higher than those in the control group on the first and third days (P <0.01), and reached the peak on the third day. Plasma S-100b levels in patients with cerebral infarction increased significantly, reaching a peak at 36 hours. The plasma levels of NSE and S-100b were positively correlated with infarct size and neurological deficit (P <0.01), and the poorer clinical efficacy was found in plasma NSE (P <0.01). CONCLUSIONS: The levels of plasma NSE and S-100b in patients with acute cerebral infarction are elevated, and the levels of NSE and S-100b are different at different stages of development. The content of NSE and S-100b can reflect the severity of cerebral infarction. NSE and S-100b can be used as brain damage Objective assessment of the degree and prognosis.